Following a full submission
AWMSG advice |
||
| Status: Superseded | ||
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED APRIL 2012. Refer to TA169: Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. AWMSG documentation provided for reference only. |
||
|
||
Medicine details |
||
| Medicine name | sunitinib (Sutent®) | |
| Formulation | capsule | |
| Reference number | 294 | |
| Indication | Treatment of advanced and/or metastatic renal cell carcinoma |
|
| Company | Pfizer Ltd | |
| BNF chapter | Malignant disease & immunosuppression | |
| Submission type | Full | |
| Status | Superseded | |
| Advice number | 0607 | |
| NMG meeting date | 12/07/2007 | |
| AWMSG meeting date | 15/08/2007 | |
| Ratification by Welsh Government | 29/08/2007 | |
| Date of issue | 07/09/2007 | |
| NICE guidance | TA169: Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma |
|